

IMPACT OF CABOTEGARVIR AND RILPIVIRINE LONG-ACTING IN QUALITY OF LIFE OF SUBJECTS IN A REAL WORLD SETTING: PRELIMINARY DATA.



Authors: S. ARNAIZ DIEZ¹, L. SANCHEZ LUQUE¹, R. PEDRERO TOME², M.P. ESPINOSA¹, M. MONTES³, J. TROYA⁴, E. BERNAL⁵, P. MASCARELL⁶, J.E. LOSA GARCIA⁷, F. TEJERINA PICADO⁸. ¹Hospital Universitario De Burgos, Farmacia Hospitalaria, Burgos, Spain. ²Hospital Infanta Leonor, Fundación Para La Investigación E Innovación Biomédica, Madrid, Spain. ³Hospital Universitario La Paz, Unidad De Enfermedades Infecciosas, Madrid, Spain. ⁴Hospital Universitario Infanta Leonor, Unidad De Enfermedades Infecciosas, Madrid, Spain . ⁵Hospital Universitario Reina Sofia, Unidad De Enfermedades Infecciosas, Murcia, Spain. ⁶Hospital General Universitario De Elche, Unidad De Enfermedades Infecciosas, Alicante, Spain. ⁷Hospital Universitario De Alcorcón, Unidad De Enfermedades Infecciosas, Alcorcon, Spain. ⁸Hospital General Universitario Gregorio Marañón, Unidad De Enfermedades Infecciosas, Madrid, Spain. **GRUPO RELATIVITY. Contact data:** sarnaizd@saludcastillayleon.es. **Abstract Number: 5PSQ-141**

BACKGROUND AND IMPORTANCE

Long-acting (LA) injectable therapy with cabotegravir (CAB) and rilpivirine (RPV) may improve quality of life. General health was assessed in clinical trials about LA CAB+RPV using the 12-Item Short Form Health Survey (SF- 12) questionnaire.

AIM AND OBJECTIVES


To describe the quality of life, according to the SF-12 questionnaire, of patients in treatment with LA CAB+RPV in real world setting.

MATERIAL AND METHODS

Study Overview

- Multicenter
- Non-controlled
- Restrospective and prospective study (Relativity cohort -HIV patients on treatment with LA CAB+RPV-)
- Time to complete the questionnaire: between 9-14 months of treatment

Survey Details: 12-Item Short Form Health Survey (SF- 12) questionnaire:




Data Collection Method

- Questionnaire administered online using QR code
- Platform: RedCap for data collection and subsequent analysis

RESULTS

- 205 patients
- 13 hospitals (Spain)
- Median age: 46.0 [38.2, 55.4] years
- 88.7% males.
- Follow-up duration: 13.1 [11.0, 15.1] months.



CONCLUSIONS

- The PCS and MCS scores are similar to those described in the healthy US population (mean of 50).
- Our data suggest that patients with LA CAB+RPV have a good state of physical and mental health.
- Longer follow-up in more patients is needed to obtain more consistent data.